Abstract Number: 2407 • 2019 ACR/ARP Annual Meeting
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 versus JAK2, JAK3, and TYK2, and is currently being assessed…